Molecular mechanisms underlying chronic inflammation-associated cancers

被引:223
|
作者
Wu, Yongzhong [1 ]
Antony, Smitha [1 ]
Meitzler, Jennifer L. [1 ]
Doroshow, James H. [1 ,2 ]
机构
[1] NCI, Lab Mol Pharmacol, NIH, Bethesda, MD 20892 USA
[2] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
NADPH oxidase; Inflammation; Reactive oxygen; Cancer; NF-KAPPA-B; OXYGEN SPECIES GENERATION; NECROSIS-FACTOR-ALPHA; DUAL OXIDASE 2; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FLAVIN DEHYDROGENASE INHIBITORS; HYDROGEN-PEROXIDE PRODUCTION; INTESTINAL EPITHELIAL-CELLS; NADPH OXIDASE; OXIDATIVE STRESS;
D O I
10.1016/j.canlet.2013.08.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although it is now accepted that chronic inflammation plays an essential role in tumorigenesis, the underlying molecular mechanisms linking inflammation and cancer remain to be fully explored. Inflammatory mediators present in the tumor microenvironment, including cytokines and growth factors, as well as reactive oxygen species (ROS) and reactive nitrogen species (RNS), have been implicated in the etiology of inflammation-associated cancers. Epithelial NADPH oxidase (Nox) family proteins, which generate ROS regulated by cytokines, are upregulated during chronic inflammation and cancer. ROS serve as effector molecules participating in host defense or as chemo-attractants recruiting leukocytes to wounds, thereby influencing the inflammatory reaction in damaged tissues. ROS can alter chromosomal DNA, leading to genomic instability, and may serve as signaling molecules that affect tumor cell proliferation, survival, metabolism, angiogenesis, and metastasis. Targeting Noxs and their downstream signaling components may be a promising approach to pre-empting inflammation-related malignancies. Published by Elsevier Ireland Ltd.
引用
收藏
页码:164 / 173
页数:10
相关论文
共 50 条
  • [1] Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis
    Ueha, Satoshi
    Shand, Francis H. W.
    Matsushima, Kouji
    FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [2] Acetamides: chemotherapeutic agents for inflammation-associated cancers
    Rani, Priyanka
    Pal, Dilipkumar
    Hegde, Rahul Rama
    Hashim, Syed Riaz
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (04) : 255 - 265
  • [3] Mechanisms and Therapeutic Strategies of Chronic Infection and Inflammation-Associated Hepatocellular Carcinoma
    Peng Zheng
    Li Chang-Fei
    Hao Jun-Li
    Meng Song-Dong
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2014, 41 (01) : 17 - 23
  • [4] Genetic Pathogenesis of Inflammation-Associated Cancers in Digestive Organs
    Nakanishi, Risa
    Shimizu, Takahiro
    Kumagai, Ken
    Takai, Atsushi
    Marusawa, Hiroyuki
    PATHOGENS, 2021, 10 (04):
  • [5] Immunological Mechanisms in Inflammation-Associated Colon Carcinogenesis
    Hirano, Takehiro
    Hirayama, Daisuke
    Wagatsuma, Kohei
    Yamakawa, Tsukasa
    Yokoyama, Yoshihiro
    Nakase, Hiroshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [6] Epigenetic mechanisms connect inflammation-associated diseases
    Telfer, Caroline
    EPIGENOMICS, 2013, 5 (03) : 249 - 249
  • [7] Cellular and Molecular Mechanisms of Phytochemicals Against Inflammation-Associated Diseases and Viral Infection
    Zheng, Zhaodi
    Gao, Junying
    Ma, Yubing
    Hou, Xitan
    CELL BIOLOGY INTERNATIONAL, 2025,
  • [8] Inflammation-associated insulin resistance: Rheumatoid arthritis and systemic lupus erythematosus as models to define underlying mechanisms
    Chung, C. P.
    Oeser, A.
    Avalos, I.
    Sokka, T.
    Solus, J.
    Raggi, P.
    Pincus, T.
    Stein, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 66 - 67
  • [9] Oncogene and non-oncogene addiction in inflammation-associated cancers
    Zheng, Min
    Jiang, Jian
    Tang, Ya-ling
    Liang, Xin-hua
    FUTURE ONCOLOGY, 2013, 9 (04) : 561 - 573
  • [10] Uncovering novel mechanisms of chitinase-3-like protein 1 in driving inflammation-associated cancers
    Fan, Yan
    Meng, Yuan
    Hu, Xingwei
    Liu, Jianhua
    Qin, Xiaosong
    CANCER CELL INTERNATIONAL, 2024, 24 (01)